True - most of biotech has been hammered since last year. That could be at least part of the explanation.
Admittedly I had been using the lowered share prices to judicially add to my stashes of things like CVM and CFRX that have treatments that are either in Phase III or have recently finished a Phase III.
I was doing the same with AMPE - but their management did some really dumb things recently with Phase III data, got their study deep-sixed by FDA review, and although I have not sold my shares in that, I have not been adding any.